ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $39.57 billion. The enterprise value is $38.92 billion.
| Market Cap | 39.57B |
| Enterprise Value | 38.92B |
Important Dates
The last earnings date was Thursday, January 29, 2026, after market close.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | Feb 12, 2026 |
Share Statistics
ResMed has 145.68 million shares outstanding. The number of shares has decreased by -0.43% in one year.
| Current Share Class | 145.68M |
| Shares Outstanding | 145.68M |
| Shares Change (YoY) | -0.43% |
| Shares Change (QoQ) | -0.36% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 72.56% |
| Float | 144.77M |
Valuation Ratios
The trailing PE ratio is 26.87 and the forward PE ratio is 23.31. ResMed's PEG ratio is 1.67.
| PE Ratio | 26.87 |
| Forward PE | 23.31 |
| PS Ratio | 7.24 |
| Forward PS | 6.75 |
| PB Ratio | 6.15 |
| P/TBV Ratio | 13.87 |
| P/FCF Ratio | 22.04 |
| P/OCF Ratio | 20.63 |
| PEG Ratio | 1.67 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.22, with an EV/FCF ratio of 21.72.
| EV / Earnings | 26.19 |
| EV / Sales | 7.21 |
| EV / EBITDA | 19.22 |
| EV / EBIT | 21.09 |
| EV / FCF | 21.72 |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.13.
| Current Ratio | 3.06 |
| Quick Ratio | 1.97 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.41 |
| Debt / FCF | 0.47 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 25.68% and return on invested capital (ROIC) is 26.60%.
| Return on Equity (ROE) | 25.68% |
| Return on Assets (ROA) | 14.75% |
| Return on Invested Capital (ROIC) | 26.60% |
| Return on Capital Employed (ROCE) | 25.44% |
| Weighted Average Cost of Capital (WACC) | 8.89% |
| Revenue Per Employee | $540,894 |
| Profits Per Employee | $148,885 |
| Employee Count | 9,980 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.15 |
Taxes
In the past 12 months, ResMed has paid $332.81 million in taxes.
| Income Tax | 332.81M |
| Effective Tax Rate | 18.30% |
Stock Price Statistics
The stock price has increased by +11.98% in the last 52 weeks. The beta is 0.88, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | +11.98% |
| 50-Day Moving Average | 252.26 |
| 200-Day Moving Average | 259.16 |
| Relative Strength Index (RSI) | 67.44 |
| Average Volume (20 Days) | 1,197,976 |
Short Selling Information
The latest short interest is 11.43 million, so 7.85% of the outstanding shares have been sold short.
| Short Interest | 11.43M |
| Short Previous Month | 10.56M |
| Short % of Shares Out | 7.85% |
| Short % of Float | 7.90% |
| Short Ratio (days to cover) | 12.40 |
Income Statement
In the last 12 months, ResMed had revenue of $5.40 billion and earned $1.49 billion in profits. Earnings per share was $10.11.
| Revenue | 5.40B |
| Gross Profit | 3.32B |
| Operating Income | 1.85B |
| Pretax Income | 1.82B |
| Net Income | 1.49B |
| EBITDA | 2.02B |
| EBIT | 1.85B |
| Earnings Per Share (EPS) | $10.11 |
Balance Sheet
The company has $1.42 billion in cash and $847.72 million in debt, with a net cash position of $569.35 million or $3.91 per share.
| Cash & Cash Equivalents | 1.42B |
| Total Debt | 847.72M |
| Net Cash | 569.35M |
| Net Cash Per Share | $3.91 |
| Equity (Book Value) | 6.32B |
| Book Value Per Share | 43.39 |
| Working Capital | 2.57B |
Cash Flow
In the last 12 months, operating cash flow was $1.91 billion and capital expenditures -$122.89 million, giving a free cash flow of $1.79 billion.
| Operating Cash Flow | 1.91B |
| Capital Expenditures | -122.89M |
| Free Cash Flow | 1.79B |
| FCF Per Share | $12.30 |
Margins
Gross margin is 61.47%, with operating and profit margins of 34.19% and 27.53%.
| Gross Margin | 61.47% |
| Operating Margin | 34.19% |
| Pretax Margin | 33.69% |
| Profit Margin | 27.53% |
| EBITDA Margin | 37.51% |
| EBIT Margin | 34.19% |
| FCF Margin | 33.19% |
Dividends & Yields
This stock pays an annual dividend of $2.40, which amounts to a dividend yield of 0.88%.
| Dividend Per Share | $2.40 |
| Dividend Yield | 0.88% |
| Dividend Growth (YoY) | 12.56% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 23.04% |
| Buyback Yield | 0.43% |
| Shareholder Yield | 1.31% |
| Earnings Yield | 3.76% |
| FCF Yield | 4.54% |
Analyst Forecast
The average price target for ResMed is $293.70, which is 8.13% higher than the current price. The consensus rating is "Buy".
| Price Target | $293.70 |
| Price Target Difference | 8.13% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 8.34% |
| EPS Growth Forecast (5Y) | 10.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 12.89 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.89 |
| Piotroski F-Score | 6 |